InfluenzaPhase 4NCT01113580

A Clinical Trial of CSL's 2010/2011 Formulation of Enzira® in a Healthy Adult Population

A Phase 4 study testing CSL's 2010/2011 Formulation of Enzira® Vaccine in people with Influenza, run by Seqirus at 1 site in United Kingdom.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record

Search all trials

Trial summary

The purpose of this study is to determine whether the 2010/2011 Formulation Enzira vaccine is safe and elicits an immune response to seasonal influenza in healthy adults. Read more about this study

Who is it for?: Ages 18 years and olderHealthy volunteers can take part
Conditions the study is for: Influenza
What is being tested?: CSL's 2010/2011 Formulation of Enzira® Vaccine
Type of treatment: Vaccines, Injection or infusion
Could I receive a placebo?: No, everyone receives an active treatment
How many people: 120 participants
Where: 1 siteUnited Kingdom
Study dates: May 2010to May 2010
Phase: Phase 4
Are there results?: Yes, posted in the registrySummary in the doctors' view

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

Ages 18 years and older
All sexes
Healthy volunteers accepted
Adult, Older adult

Who may be able to join

Male or female aged 18 years and older at the time of the first study vaccination.

Who cannot join

Known hypersensitivity to a previous dose of influenza virus vaccine or allergy to eggs, chicken protein, neomycin, polymyxin, or any components of the Study Vaccine.
Clinical signs of an active infection
Vaccination with a seasonal or experimental influenza virus vaccine in the 6 months preceding study entry
Females who are pregnant or lactating

Trial locations and contacts

1 site in 1 country.

United Kingdom1 site

Chiltern (Early Phase) Limited
Dundee, Angus and Dundee, DD1 9SY

Other trials in United Kingdom

About this study

Official title: A Phase IV, Single-centre, Open-label Study to Evaluate the Immunogenicity and Safety of the 2010/2011 Formulation of Enzira® Vaccine in Two Groups of Healthy Volunteers: 'Adults' (Aged 18 to 59 Years) and 'Older Adults' (Aged 60 Years or Older)

The purpose of this study is to determine whether the 2010/2011 Formulation Enzira vaccine is safe and elicits an immune response to seasonal influenza in healthy adults.

Conditions: Influenza
Being tested: CSL's 2010/2011 Formulation of Enzira® Vaccine
Medical subject headings: Influenza, Human

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

CSL's 2010/2011 Formulation of Enzira® VaccineBiological
45 mcg of HA antigen in 0.5 mL administered by intramuscular injection into the deltoid region of the arm on Day 0

Study groups in NCT01113580
Study group	Role	What they receive
Adults	Experimental	Healthy volunteers aged 18 to 59 years Receives: Biological: CSL's 2010/2011 Formulation of Enzira® Vaccine
Older Adults	Experimental	Healthy volunteers aged 60 years or older Receives: Biological: CSL's 2010/2011 Formulation of Enzira® Vaccine

What is being measured

The primary outcome is the main question the study is designed to answer.

The Percentage of Evaluable Participants Achieving Seroconversion or Significant Increase in Antibody Titre.
As per the criteria specified in the CPMP/BWP/214/96 Note for Guidance on Harmonisation of Requirements for Influenza Vaccines. For haemagglutination inhibition (HI), seroconversion is defined as achieving a post-vaccination titre of ≥ 40 for those participants with a pre-vaccination HI titre of < 10; significant increase is defined as a four-fold or greater increase in HI titre for those participants with a pre-vaccination HI titre of ≥ 10.
Measured: Approximately 21 days after vaccination
The Geometric Mean Fold Increase (GMFI) in Antibody Titre After Vaccination.
GMFI is defined as the geometric mean of the fold increases of post-vaccination antibody titre over the pre-vaccination antibody titre.
Measured: Approximately 21 days after vaccination
The Percentage of Evaluable Participants Achieving a HI Titre ≥ 40 or Single Radial Haemolysis (SRH) Area ≥ 25 mm2.
Measured: Approximately 21 days after vaccination

Secondary outcomes (2)

Frequency of Any Solicited Adverse Events (AEs)
The number of participants reporting any solicited AEs.
Measured: During the 4 days after vaccination (Day 0 plus 3 days)
Frequency and Intensity of Any Unsolicited Adverse Events
Unsolicited adverse event (UAE) grading:
Mild: Symptoms were easily tolerated and there was no interference with daily activities. Moderate: Enough discomfort to have caused some interference with daily activities. Severe: Symptoms that prevented normal, everyday activities.
Measured: After vaccination until the end of the study; approximately 21 days

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

May 2010May 2010

First posted30 Apr 2010 (estimated)
Study startMay 2010
Primary completionMay 2010
Study completionMay 2010

Resources

Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
Posted resultsParticipant flow, outcome measures and adverse events reported by the sponsor.
Other trials for InfluenzaStudies of the same condition, open and under way.
What the trial phases meanHow a treatment moves from first tests in people to approval.

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design

Study type: Interventional
Phase: Phase 4
Primary purpose: Prevention
Allocation: Non-randomised
Intervention model: Parallel groups
Masking: None (open label)
Enrolment: 120 participants (actual)

IDs, dates and publications

ClinicalTrials.gov ID: NCT01113580
Sponsor's protocol ID: CSLCT-ASU-10-66
Other IDs: 2010-019532-12
Status last verified: Oct 2017
First submitted: 26 Apr 2010
Last updated: 21 Nov 2017
Results posted: Yes, on ClinicalTrials.gov
Data monitoring committee: No

Want to know more?

The sponsor has not listed a contact. The official record may have more details.

Talk to your doctor first and take this page with you. Only the study team can confirm whether you can join.

Questions to ask the study team

What is the study trying to find out?
What would I need to do, and how often would I visit?
Could I receive a placebo instead of the treatment?
What are the possible risks and benefits for me?
Will it cost me anything? Are travel or time paid for?
Can I keep seeing my own doctor during the study?
What happens when the study ends?

See locations

Enrolling by invitation
Personalized Ventilator Settings for Patients on ECMO
Acute Respiratory Distress Syndrome (ARDS), Extracorporeal Membrane Oxygenation
RecruitingPhase 2
BPL-1357 Against H1N1 Influenza Virus Challenge
Influenza, Human
Not yet recruitingPhase 1
Safety and Immunogenicity of Chimeric Hemagglutinin mRNA Vaccine Candidates
Influenza
RecruitingPhase 1
pH1N1 Blinded Challenge Study
Influenza
RecruitingPhase 3
A Study to Evaluate the Safety and Efficacy of MK-1406/CD388 for Prevention of Influenza (MK-1406-005/CD388.SQ.3.06)
Influenza

All Influenza trials

Study at a glance

From the registry record, last updated by the sponsor on 21 Nov 2017. Recruitment status is as the sponsor reported it: confirm with the study team.

Official title: A Phase IV, Single-centre, Open-label Study to Evaluate the Immunogenicity and Safety of the 2010/2011 Formulation of Enzira® Vaccine in Two Groups of Healthy Volunteers: 'Adults' (Aged 18 to 59 Years) and 'Older Adults' (Aged 60 Years or Older)
ClinicalTrials.gov ID: NCT01113580
Acronym / sponsor ID: CSLCT-ASU-10-66
Conditions: Influenza
Phase: Phase 4
Study type: Interventional
Recruitment status: Completed
Enrolment: 120 participants (actual)
Lead sponsor: SeqirusIndustry (pharma, biotech, devices)
Study start: May 2010
Primary completion: May 2010 (actual)
Study completion: May 2010 (actual)
First posted: 30 Apr 2010 (estimated)
Results: Posted 18 Jul 2012

Clinical summary

The research question as the sponsor registered it. This describes what the study plans to test, not what it found.

The purpose of this study is to determine whether the 2010/2011 Formulation Enzira vaccine is safe and elicits an immune response to seasonal influenza in healthy adults.

Study design

Primary purpose: Prevention
Allocation: Non-randomised
Intervention model: Parallel groups
Masking: None (open label)
Number of arms: 2

Arm	Type	Receives
Adults	Experimental	Biological: CSL's 2010/2011 Formulation of Enzira® VaccineHealthy volunteers aged 18 to 59 years
Older Adults	Experimental	Biological: CSL's 2010/2011 Formulation of Enzira® VaccineHealthy volunteers aged 60 years or older

Who may qualify

Ages: 18 years and older
Sex: All
Healthy volunteers: Accepted
Age groups: Adult, Older adult

Key inclusion criteria (1 listed)

Male or female aged 18 years and older at the time of the first study vaccination.

Key exclusion criteria (4 listed)

Known hypersensitivity to a previous dose of influenza virus vaccine or allergy to eggs, chicken protein, neomycin, polymyxin, or any components of the Study Vaccine.
Clinical signs of an active infection
Vaccination with a seasonal or experimental influenza virus vaccine in the 6 months preceding study entry
Females who are pregnant or lactating

Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.

Interventions

Intervention	Type	Arms
CSL's 2010/2011 Formulation of Enzira® Vaccine45 mcg of HA antigen in 0.5 mL administered by intramuscular injection into the deltoid region of the arm on Day 0	Biological	Adults, Older Adults

Primary outcome

The Percentage of Evaluable Participants Achieving Seroconversion or Significant Increase in Antibody Titre.
Time frame: Approximately 21 days after vaccination
As per the criteria specified in the CPMP/BWP/214/96 Note for Guidance on Harmonisation of Requirements for Influenza Vaccines. For haemagglutination inhibition (HI), seroconversion is defined as achieving a post-vaccination titre of ≥ 40 for those participants with a pre-vaccination HI titre of < 10; significant increase is defined as a four-fold or greater increase in HI titre for those participants with a pre-vaccination HI titre of ≥ 10.
The Geometric Mean Fold Increase (GMFI) in Antibody Titre After Vaccination.
Time frame: Approximately 21 days after vaccination
GMFI is defined as the geometric mean of the fold increases of post-vaccination antibody titre over the pre-vaccination antibody titre.
The Percentage of Evaluable Participants Achieving a HI Titre ≥ 40 or Single Radial Haemolysis (SRH) Area ≥ 25 mm2.
Time frame: Approximately 21 days after vaccination

2 secondary outcomes

Frequency of Any Solicited Adverse Events (AEs)
Time frame: During the 4 days after vaccination (Day 0 plus 3 days)
Frequency and Intensity of Any Unsolicited Adverse Events
Time frame: After vaccination until the end of the study; approximately 21 days

Results and safety

Results posted to the registry on 18 Jul 2012, as reported by the sponsor. Figures are copied from the record, not re-analysed. Full results on ClinicalTrials.gov.

Participant flow

Group	Started	Completed
Adults	60	59
Older Adults	60	60

Primary outcome: The Percentage of Evaluable Participants Achieving Seroconversion or Significant Increase in Antibody Titre.

Time frame: Approximately 21 days after vaccination. Number (95% Confidence Interval). Unit: Percentage of participants

Measure	Adults n = 58	Older Adults n = 60
A/California/7/2009 (H1N1)-like strain	89.7 (78.8 to 96.1)	80.0 (67.7 to 89.2)
A/Perth/16/2009 (H3N2)-like strain	89.7 (78.8 to 96.1)	71.7 (58.6 to 82.5)
B/Brisbane/60/2008-like strain	63.8 (50.1 to 76.0)	28.3 (17.5 to 41.4)

Population analysed: The Evaluable Population comprised all participants who were vaccinated with the study vaccine, provided both pre- and post-vaccination antibody titre results, and were not excluded from the analyses (eg, for the use of a prohibited medication or a laboratory-confirmed influenza virus infection between Visits 1 and 2).

Primary outcome: The Geometric Mean Fold Increase (GMFI) in Antibody Titre After Vaccination.

Time frame: Approximately 21 days after vaccination. Number (95% Confidence Interval). Unit: Fold increase

Measure	Adults n = 58	Older Adults n = 60
A/California/7/2009 (H1N1)-like strain	20.48 (14.714 to 28.512)	12.90 (8.218 to 20.239)
A/Perth/16/2009 (H3N2)-like strain	24.70 (16.967 to 35.958)	11.53 (7.313 to 18.191)
B/Brisbane/60/2008-like strain	6.63 (4.598 to 9.571)	2.77 (2.055 to 3.747)

Primary outcome: The Percentage of Evaluable Participants Achieving a HI Titre ≥ 40 or Single Radial Haemolysis (SRH) Area ≥ 25 mm2.

Time frame: Approximately 21 days after vaccination. Number (95% Confidence Interval). Unit: Percentage of participants

Measure	Adults n = 58	Older Adults n = 60
A/California/7/2009 (H1N1)-like strain	91.4 (81.0 to 97.1)	90.0 (79.5 to 96.2)
A/Perth/16/2009 (H3N2)-like strain	98.3 (90.8 to 100.0)	96.7 (88.5 to 99.6)
B/Brisbane/60/2008-like strain	89.7 (78.8 to 96.1)	70.0 (56.8 to 81.2)

2 secondary outcomes are reported in the full results.

Adverse events

Time frame: Approximately 21 days after study vaccination for serious adverse events and unsolicited adverse events.. Other adverse events reported at 2.0% frequency or more

Group	Serious adverse events	Other adverse events	Deaths
Adults	0 of 60 (0%)	22 of 60 (36.7%)	Not reported
Older Adults	0 of 60 (0%)	15 of 60 (25%)	Not reported

Loading the posted results from ClinicalTrials.gov…

Research links

Official record on ClinicalTrials.govLast updated by the sponsor 21 Nov 2017.
Posted resultsParticipant flow, baseline, all outcome measures and adverse events.

Related trials for Influenza

Enrolling by invitation
Personalized Ventilator Settings for Patients on ECMO
Acute Respiratory Distress Syndrome (ARDS), Extracorporeal Membrane Oxygenation
RecruitingPhase 2
BPL-1357 Against H1N1 Influenza Virus Challenge
Influenza, Human
Not yet recruitingPhase 1
Safety and Immunogenicity of Chimeric Hemagglutinin mRNA Vaccine Candidates
Influenza
RecruitingPhase 1
pH1N1 Blinded Challenge Study
Influenza
RecruitingPhase 3
A Study to Evaluate the Safety and Efficacy of MK-1406/CD388 for Prevention of Influenza (MK-1406-005/CD388.SQ.3.06)
Influenza

Referral and contact

AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.

Ronnie Beboso, Dr principal investigator

Chiltern (Early Phase) Limited

1 site in 1 country: see every site and its status.

Questions about this trial

What is this clinical trial studying?

A Phase 4 study testing CSL's 2010/2011 Formulation of Enzira® Vaccine in people with Influenza, run by Seqirus at 1 site in United Kingdom.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 1 inclusion and 4 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 21 Nov 2017. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in United Kingdom. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

What does this phase mean?

Phase 4 studies take place after a treatment is approved, to learn more about its long-term benefits and risks in everyday use.

Not every study follows the same path, and some studies (observational studies, device studies) have no phase.

Are results available for this study?

Yes. Results are posted in the registry (first posted 18 Jul 2012). A summary is in the For doctors view, and the full results are on ClinicalTrials.gov.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

The Percentage of Evaluable Participants Achieving Seroconversion or Significant Increase in Antibody Titre. (time frame: Approximately 21 days after vaccination). The study lists 3 primary outcomes in all. It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT01113580.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 21 Nov 2017.